All In Biotech

Drug Trial Radar · NCT06488313

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

A Phase 2a, Open-label, Multiple Ascending Dose Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency

Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Nov 4, 2024

Primary completion

Jun 1, 2026

Study completion Sep 1, 2026

Sponsor

Lead sponsor
Arcturus Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.

Conditions

  • OTC Deficiency
  • Ornithine Transcarbamylase Deficiency
  • OTCD

Interventions

  • ARCT-810Biological

    ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity and dose-relationship of adverse events (AEs)Time frame: Day 85

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Uncommon Cures

    Chevy Chase, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.